Trial Profile

Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 22 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trenonacog alfa (Primary)
Indications Haemophilia B
Focus Therapeutic Use
Sponsors Cangene Corporation; Emergent BioSolutions; Inspiration Biopharmaceuticals; Medexus Pharmaceuticals

Most Recent Events

20 Mar 2019 Status changed from completed to discontinued.
05 Jun 2017 Status changed from active, no longer recruiting to completed.
13 Dec 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Feb 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com